The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.

The present invention relates to a novel and unexpected method of using topical Capecitabine composition to obtain therapeutically effective amounts of fluorouracil (FU) within the skin of a subject afflicted with hyperproliferative or inflammatory skin condition. The method comprising topically administering a pharmaceutical composition comprising Capecitabine or a hydrate or solvate thereof to the affected area of the skin of the subject, to form therapeutically effective amounts of FU within the skin.

This invention relates to a novel method of treating solid tumors of the head and neck. More specifically, the invention relates to the use of Momordicine-I (M-I), an extract of bitter melon (Momordica charantia), to treat solid tumors, particularly those of the head and neck as well as the breast. Methods and compositions are disclosed related to administrating Momordicine-I with lipophilic solvents to subjects in need.

This invention relates to a novel method of treating solid tumors of the head and neck. More specifically, the invention relates to the use of Momordicine-I (M-I), an extract of bitter melon (Momordica charantia), to treat solid tumors, particularly those of the head and neck as well as the breast. Methods and compositions are disclosed related to administrating Momordicine-I with lipophilic solvents to subjects in need.

The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.

A beverage composition promotes cellular hydration when ingested by a multicellular organism, and includes a carbohydrate clathrate component that includes cyclodextrin, in a concentration of 0.01-5% w/w. A complex-forming compound is also included in a concentration that is less than the clathrate component, and there is an aqueous liquid component, such as still and carbonated aqueous liquids. An inclusion complex is formed with at least some of the clathrate component and at least some of the complex-forming compound and the composition promotes cellular hydration of the multicellular organism when the multicellular organism ingests it. There is also a beverage composition that increases lifespan in the multicellular organism, and methods of promoting cellular hydration and increasing lifespan of the multicellular organism according to a mechanism of action.

A composition containing black ginger extract including black ginger extract, and cyclodextrin. The composition containing black ginger extract includes certain 6 polymethoxyflavones (6PMF). When a total amount of 6PMF in the composition containing black ginger extract is determined as 100 parts by mass, an amount of 5-hydroxy-7-methoxyflavone in the composition containing black ginger extract is 5 parts by mass or less. When absorbance of an aqueous solution of the composition containing black ginger extract, in which a total amount of the 6 polymethoxyflavones is adjusted to a certain amount, is measured, the absorbance of the aqueous solution satisfies P1/V1≥1.45.

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable alkanesulphonate salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.